This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Osiris Stem Cell Therapy Fails Diabetes Trial

COLUMBIA, Md. ( TheStreet) -- Another clinical trial, another failure for Osiris Therapeutics (OSIR - Get Report) and its do-nothing stem cell therapy.

This time, Osiris' experimental Prochymal therapy failed to slow the progression of Type 1 diabetes compared to a placebo after one year of treatment.

Add diabetes to the long list of diseases in which Prochymal has proven to be ineffective, including graft-versus-host disease, knee cartilage repair, Crohn's disease and heart attack.

Osiris never likes to acknowledge Prochymal's many failures and Tuesday's announcement of the diabetes trial result is no different. The company buried the study's disappointing data in its press release: "No significant differences in the rates of disease progression, as measured by stimulated C-peptide levels at the one year time point, have been observed."

Prochymal's side effect profile was apparently as benign as placebo, which makes sense since Prochymal -- a stew of off-the-shelf adult stem cells that gets injected into patients -- has proven to be nothing more than a placebo.

Osiris notes a "trend" towards fewer incidences of low blood sugar reported by Prochymal-treated patients compared to those treated with a placebo at one year. What Osiris doesn't say is that having something vaguely positive to report about one of six secondary endpoints matters not at all when the study's primary endpoint fails.

Efforts by Osiris to convince regulators in Canada to approve Prochymal in graft-versus-host disease appear stalled and the company has said nothing recently about moving forward with a U.S. approval filing for the same indication.

Osiris finds it easier apparently to bamboozle retail investors about failed stem-cell therapies than regulators.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
OSIR $5.02 -5.80%
AAPL $94.30 -0.92%
FB $118.08 0.55%
GOOG $695.81 0.50%
TSLA $234.18 0.80%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs